Results 51 to 60 of about 43,876 (313)
Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease [PDF]
, 2017 Available cholinergic drugs for treating Alzheimer's disease (AD) provide modest symptomatic benefit. We hypothesized that co-administration of a peripheral anticholinergic to reduce dose-limiting adverse effects (AEs) would enable the safe/tolerable use
Chase, Thomas N. +2 more
core +1 more source
A review of clinical treatment considerations of donepezil in severe Alzheimer's disease
CNS Neuroscience & Therapeutics, 2018 Alzheimer's disease (AD) is a neurodegenerative disorder that affects over 45 million people worldwide. Patients with severe AD require help with daily activities and show severe memory impairment. Currently, donepezil is one of two drugs approved by FDA
A. Adlimoghaddam +3 more
semanticscholar +1 more source
Effects of non-pharmacological or pharmacological interventions on cognition and brain plasticity of aging individuals. [PDF]
, 2014 Brain aging and aging-related neurodegenerative disorders are major health challenges faced by modern societies. Brain aging is associated with cognitive and functional decline and represents the favourable background for the onset and development of ...
Cesinaro, Stefano +4 more
core +2 more sources
Dementia and Geriatric Cognitive Disorders Extra, 2016 Background: The ‘Asia-Pacific Expert Panel (APEX) for donepezil 23 mg' met in November 2015 to review evidence for the recently approved high dose of donepezil and to provide recommendations to help physicians in Asia make informed clinical decisions ...
Marwan Sabbagh +13 more
doaj +1 more source
Molecules, 2021 Gastrointestinal side effects of donepezil, including dyspepsia, nausea, vomiting or diarrhea, occur in 20–30% of patients. The pathogenesis of these dysmotility associated disorders has not been fully clarified yet.
Jan Bures +14 more
doaj +1 more source
Nasal delivery of donepezil HCl-loaded hydrogels for the treatment of Alzheimer’s disease
Scientific Reports, 2019 This study aims to prepare, characterize and evaluate the pharmacokinetics of liposomal donepezil HCl (LDH) dispersed into thiolated chitosan hydrogel (TCH) in rabbits.
Sitah Al Harthi +4 more
semanticscholar +1 more source
Brazilian Journal of Pharmaceutical Sciences, 2020 Alzheimer disease (AD) is characterized by a low level of acetylcholine, beta-amyloid (Aβ) aggregation and oxidative stress. Donepezil is the core medicine used for the treatment of AD. Various structural modifications of donepezil have been carried out.
N. Mohsin, Matloob Ahmad
semanticscholar +1 more source
Prolonged cholinergic enrichment influences regional cortical activation in early Alzheimer's disease [PDF]
, 2008 Neuroimaging studies of cholinesterase inhibitor (ChEI) treatment in Alzheimer's disease (AD) indicate that the short and long term actions of ChEIs are dissimilar. fMRI studies of the ChEI rivastigmine have focused on its short term action.
McGeown, William J +2 more
core +2 more sources
Convulsions induced by donepezil [PDF]
Journal of Neurology, Neurosurgery & Psychiatry, 1999 Donepezil, a centrally acting acetylcholinesterase inhibitor, has been recently introduced for the symptomatic relief of cognitive impairment in patients with mild to moderate Alzheimer’s disease. Several adverse events thought to be related to donepezil have been reported so far, the most common ones being gastrointestinal disturbances due to ...
N Zurak, T Babic
openaire +2 more sources
Harnessing Photo‐Energy Conversion in Nanomaterials for Precision Theranostics
Advanced Materials, EarlyView.Harnessing photo‐energy conversion in nanomaterials enables precision theranostics through light‐driven mechanisms such as photoluminescence, photothermal, photoelectric, photoacoustic, photo‐triggered surface‐enhanced Raman scattering (SERS), and photodynamic processes. This review explores six fundamental principles of photo‐energy conversion, recent
Jingyu Shi +4 more
wiley +1 more source